OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder

Inclusion Criteria:

-Patients with symptoms of Overactive Bladder (OAB) (frequency and urgency) with urinary
incontinence for at least 6 months prior to screening.

Exclusion Criteria:

- Symptoms of OAB due to a neurological reason

- Use of anticholinergics or other medications or therapies to treat symptoms of OAB
within 7 days of screening

- Use of Clean Intermittent Catheterization (CIC) or indwelling catheter to manage
urinary incontinence

- Use of botulinum toxin therapy of any serotype for any urological condition

- Use of botulinum toxin therapy of any serotype for any non-urological condition in the
12 weeks prior to screening

- History of any pelvic or urological abnormalities, bladder surgery or disease, other
than OAB, that may affect bladder function

- Diagnosis of Myasthenia gravis, Eaton-Lambert syndrome, or Amyotrophic Lateral
Sclerosis.